SHR0302 and Steroid As First Line Therapy for Chronic GVHD

Inclusion Criteria: * ≥ 18 years old and ≤ 70 years old, male or female; * Patients receiving allogeneic peripheral blood stem cell transplantation for hematological diseases; * The primary hematological malignancies are completely relieved and are expected to be stable for at least 3 months; * Chronic GVHD that was first attacked after transplantation and at least 100 days after transplantation, reached a moderate or severe level by NIH classification; * There was no previous systemic treatment (including in vitro illumination \[ECP\]); * The patient may be receiving other immunosuppressive agents to prevent or treat acute GVHD, but if the subject receives prednisone to prevent or treat acute GVHD, it must be \<0.5 mg/kg/d or equivalent dose of other glucocorticoids; * The chronic GVHD that has started hormone therapy does not exceed 72 hours; * Karnofsky score \> 60 points; * Patients must be able to understand and are willing to participate in the study and sign an informed consent form. Exclusion Criteria: * Can not tolerate prednisone dose 1mg / kg / d or equivalent dose of other glucocorticoids for the treatment of cGVHD; * Receive any systemic treatment of cGVHD, except for corticosteroids that treat cGVHD within 72 hours prior to the signing of informed consent; * Patients with GVHD overlap syndrome (NIH criteria); * Treatment of acute GVHD has received other Jak inhibitors such as ruxolitinib; * Pregnant or lactating women; * The patient is judged by the investigator to have complications that may cause other risks; * The patient is receiving other study medications; * Patient blood routine: ANC \<1.0 × 109 / L or PLT \< 50 × 109 / L; * Non-GVHD-related liver damage: the aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio is more than 3 times normal or the direct bilirubin normal value is more than 3 times; * Renal dysfunction: endogenous creatinine clearance (Ccr) \< 50mL/min or normal serum creatinine 1.5 times or more, regardless of hemodialysis treatment; * Uncontrolled infections: hemodynamic instability associated with infection, or new signs or signs of infection, or new infections in imaging, persistent fever without symptoms or signs and cannot be ruled out Infected person * People living with HIV; * Active hepatitis B (HBV), active hepatitis C (HCV) requires antiviral therapy; patients with HBV activation risk refer to patients with hepatitis B surface antigen-positive or core antibody-positive patients who are not treated with anti-HBV; * The patient's primary malignant disease recurs and the graft is rejected; * Those who are allergic to known JAK inhibitors.